FDA Approval, Nurses, Pharmacokinetics and Vaccine

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

FDA Approval

Nurses

Pharmacokinetics

Vaccine

First-in-human clinical trial for a vaccine to treat opioid use.

The Pharma Data

SEPTEMBER 7, 2021

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by researchers at the University of Minnesota Medical School. The vaccine currently being tested stimulates the body’s immune system to produce antibodies to oxycodone.

Clinical Trials

Clinical Trials Vaccine Trials Medical Schools

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

JANUARY 26, 2021

BLAZE-4 Additionally, initial results from the ongoing BLAZE-4 trial provide viral load and pharmacodynamic/pharmacokinetic data which demonstrated lower doses, including bamlanivimab 700 mg and etesevimab 1400 mg together, are similar to bamlanivimab 2800 mg and etesevimab 2800 mg together. It remains under review by the FDA.

Hospitals

Hospitals Treatment Long-Term Care Facilities Trials

Drug Discovery Digest

First-in-human clinical trial for a vaccine to treat opioid use.

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

Stay Connected